Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study

BACKGROUND: Trastuzumab given intravenously in combination with chemotherapy is standard of care for patients with early HER2-positive breast cancer (BC). Different randomised studies have shown equivalent efficacy of a subcutaneous injection into the thigh compared to the intravenous formulation. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinisch, Mattea, Untch, Michael, Mahlberg, Rolf, Reimer, Toralf, Hitschold, Thomas, Marmé, Frederik, Aydogdu, Mustafa, Schmatloch, Sabine, Lück, Hans-Joachim, Schmidt, Marcus, Ladda, Ekkehart, Sinn, Bruno Valentin, Klare, Peter, Janni, Wolfgang, Jackisch, Christian, Denkert, Carsten, Seiler, Sabine, Göhler, Thomas, Michel, Laura, Burchardi, Nicole, Stickeler, Elmar, Rey, Julia, Klutinus, Nicole, Möbus, Volker, Loibl, Sibylle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563210/
https://www.ncbi.nlm.nih.gov/pubmed/36223695
http://dx.doi.org/10.1016/j.breast.2022.10.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563210/
https://www.ncbi.nlm.nih.gov/pubmed/36223695
http://dx.doi.org/10.1016/j.breast.2022.10.002

Ejemplares similares